Top Page
Alterity Therapeutics
(Sydney:ATH)
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Alterity Therapeutics Business Overview & Revenue Model
Alterity Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.44M | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 5.31M | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -14.63M | -14.63M | -19.46M | -17.51M | -17.39M | -19.36M |
| Net Income | -12.15M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | ||||||
| Total Assets | 46.03M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 40.66M | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 155.46K | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 3.62M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 42.40M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | ||||||
| Free Cash Flow | -10.71M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -10.71M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | -7.50M | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 25.54M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$87.03M | 12.69 | 27.24% | 2.81% | 0.65% | -9.90% | |
52 Neutral | AU$190.86M | -7.27 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$113.52M | -1.09 | -83.09% | ― | ― | 55.94% | |
46 Neutral | AU$140.87M | -6.44 | -81.03% | ― | -20.79% | 73.98% | |
44 Neutral | AU$106.91M | -12.50 | -47.98% | ― | 700.00% | 26.88% | |
41 Neutral | AU$87.00M | -5.26 | -42.68% | ― | ― | 63.46% |
Alterity Therapeutics Corporate Events
Alterity Therapeutics reported that it successfully completed its Phase 2 clinical program for lead candidate ATH434 in multiple system atrophy during 2025, with data showing the drug was safe, well-tolerated, and associated with slowing disease progression across several clinical endpoints, including functional measures, mobility, and orthostatic hypotension. Building on these results, the company is now preparing for an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize a Phase 3 trial design, scaling its clinical, manufacturing, and regulatory infrastructure and deepening engagement with key neurologists, while also strengthening its board and leadership team to support potential late-stage development and future commercialization.
The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics Limited has notified the market of the issue of 43.5 million unlisted options under an employee incentive scheme, with an exercise price of US$0.0057 and an expiry date of 13 January 2031. The options, which will not be quoted on the ASX, reflect the company’s continued use of equity incentives to align employees with shareholder interests and may contribute to future dilution if exercised, signaling an ongoing focus on incentivising key personnel during its development phase.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics has notified the market of the issue of 18 million unlisted options under its employee incentive scheme, each exercisable at $0.008 and expiring on 9 January 2031. The move expands the company’s pool of unquoted equity-based incentives, signalling continued reliance on options to motivate employees and align staff interests with long-term shareholder value, while incrementally increasing potential future dilution for existing investors.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics has released a brief corporate communication noting that some of its January 2026 corporate presentation may include statements that qualify as forward-looking under U.S. securities laws. The company cautions that such statements, including any financial projections or discussions of strategic plans and objectives, are subject to risks and uncertainties that could cause actual results to differ materially, and it directs investors to its 2025 Form 20-F risk factors for further detail, underscoring the regulatory and risk-awareness context around its investor communications.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics has announced the expiry of 91,392,720 unexercised options (ASX code ATHAAD) with an exercise price of A$0.032, which lapsed on 6 January 2026. The cessation of these options removes a substantial block of potential dilution from the company’s capital structure, slightly simplifying its issued capital and clarifying the near‑term equity overhang for existing shareholders and prospective investors.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
Alterity Therapeutics Limited has announced the appointment of Julian Barbaczy as a director, effective November 21, 2025. The initial director’s interest notice indicates that Barbaczy does not hold any relevant interests in securities as a registered or non-registered holder, nor does he have any interests in contracts related to the company. This announcement is part of the company’s compliance with listing rules and corporate governance practices, ensuring transparency and accountability in its management structure.
Alterity Therapeutics Limited has announced the appointment of David Stamler as a director, effective November 21, 2025. This appointment is accompanied by a detailed disclosure of Stamler’s interests in the company’s securities, which include a significant number of fully paid ordinary shares and various options. This move is likely to impact the company’s governance and could influence its strategic direction, reflecting the company’s ongoing commitment to strengthening its leadership team.
Alterity Therapeutics Limited announced the cessation of Brian Meltzer as a director, effective November 21, 2025. This change in leadership involves Meltzer’s interests in a significant number of securities, including fully paid ordinary shares and various options, which may impact the company’s governance and strategic direction.
Alterity Therapeutics Limited has announced that Geoffrey Kempler has ceased to be a director as of November 21, 2025. The announcement details Kempler’s interests in securities, which include fully paid ordinary shares and unlisted options. This change in directorship may influence the company’s strategic direction and investor confidence, given Kempler’s significant holdings and involvement in the company.
Alterity Therapeutics announced the results of its 2025 Annual General Meeting, highlighting the approval of resolutions by shareholders. The company continues to make strides in its clinical trials, particularly with ATH434, which has shown positive results in treating Multiple System Atrophy, potentially enhancing its market position and impact on stakeholders.
Alterity Therapeutics has released a presentation by CEO Dr. David Stamler, emphasizing the company’s strategic direction and potential growth opportunities. The presentation highlights the company’s focus on advancing its objectives, though it acknowledges the inherent risks and uncertainties that could impact future outcomes.
Alterity Therapeutics announced significant progress at its 2025 Annual General Meeting, highlighting the completion of Phase 2 clinical trials for its lead asset, ATH434, in treating Multiple System Atrophy. The trials demonstrated a meaningful reduction in disease progression, earning FDA Fast Track and Orphan Drug Status, indicating strong commercial potential and hope for patients. The company is poised for late-stage clinical and commercial growth, with leadership transitions marking a new chapter in its journey.
Alterity Therapeutics has announced significant changes to its Board of Directors as it prepares for its next phase of growth, particularly advancing towards Phase 3 clinical development. Founding shareholder and former CEO Geoffrey Kempler is retiring, marking the end of a transformative era for the company. Brian Meltzer, a long-serving director, is also retiring. The company has appointed Dr. David Stamler as Managing Director and CEO, and Julian Barbaczy as Non-Executive Chair, both bringing extensive experience to support Alterity’s strategic vision and late-stage clinical development. These changes are aimed at ensuring continuity of governance and supporting the company’s drive towards meaningful outcomes for patients and shareholders.
Alterity Therapeutics Limited has disclosed a notice from Regal Funds Management Asia Pte Limited in compliance with the Australian Takeovers Panel Guidance Note 20 on Equity Derivatives. This disclosure involves long equity derivative positions related to Alterity’s securities, highlighting a significant stake held by the investment manager, which may impact the company’s market perception and investor relations.
Alterity Therapeutics announced that its CEO, David Stamler, will present a corporate update at the Bell Potter Healthcare Virtual Conference, highlighting the company’s advancements in neurodegenerative disease treatments. This presentation underscores Alterity’s commitment to addressing Parkinsonian disorders and its strategic positioning in the biotechnology sector, potentially impacting stakeholders by showcasing its clinical progress and future prospects.
Alterity Therapeutics presented promising data on ATH434 at the 36th International Symposium on the Autonomic Nervous System, highlighting its impact on orthostatic hypotension (OH) and disease progression in Multiple System Atrophy (MSA). The Phase 2 trial results showed that ATH434 stabilizes symptoms and enhances efficacy, particularly in the higher dose group, offering valuable insights for Phase 3 development. This progress underscores ATH434’s potential as a meaningful treatment option for MSA, with ongoing planning for Phase 3 trials and upcoming FDA interactions.
Alterity Therapeutics has reported promising results from its ATH434 trials, indicating a strengthened efficacy signal at high doses and a potential market opportunity of USD $2.4 billion in MSA treatment. The company is actively engaging with the FDA to advance ATH434 to Phase 3 trials, with a cash balance of A$54.56M as of September 2025, underscoring its commitment to developing a first-in-class therapy for MSA.